Monitor for additional proxy solicitation materials or a dissident filing (DFAN14A) that may detail the opposing candidate or proposals. The contested election introduces governance uncertainty but no immediate financial impact.
NRXP drugs
NRXP drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $2.38entry
- T+1 · 8d ago 0.00%α −2.37% · $2.38
- T+5 · 4d ago −7.98%α −10.58% · $2.19
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
NRX Pharmaceuticals filed additional definitive proxy soliciting materials (DEFA14A) on the same day as its definitive proxy statement (DEF 14A), indicating a contested director election for the 2026 annual meeting. The filing itself contains only the form header and no substantive soliciting content, but the cross-filing context confirms the election of Dennis McBride as the sole Class II director is being contested, adding governance uncertainty.
Key Financial Metrics
Key Facts
- Filed DEFA14A on 2026-11-05, same day as DEF 14A
- DEF 14A seeks to elect Dennis McBride as sole Class II director
- Cross-filing context indicates a contested election
- Market cap is $97M with normal daily move of 4.8%
Financial Impact
No financial figures stated in the filing
Risk Factors
- Contested election may lead to increased proxy solicitation costs
- Potential for board instability if dissident slate gains traction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001437749-26-035308 |
| Document: 0001437749-26-035308-index-headers.html | 0001437749-26-035308 |
| Document: 0001437749-26-035308-index.html | 0001437749-26-035308 |
| Document: 0001437749-26-035308.txt | 0001437749-26-035308 |
Track record
22 reports on NRXP
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Viewing Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers